Time and again, Canadians reaffirm their belief in the basic principle of equitable access to health care for all. But the spirit of this very Canadian principle remains in peril as NAFTA negotiations forge ahead.
India must resist pressure from Japan and South Korea in RCEP for the elevated levels of intellectual property provisions and make sure the deal doesn’t limit the production of life-saving generic drugs in India and for many other developing countries of the world.
AIDS, cancer, religious-based, teacher, and retiree advocacy groups were among the more than 100 organizations that recently signed a letter warning health and trade ministers of the United States, Canada, and Mexico not to undermine NAFTA’s access to affordable medicines.
It is now time we open up the dialogue on the kind of trade agreements that we want to see in place.
India and Cambodia clinch a deal to work towards a Bilateral Investment Treaty which provides financial help to Southeast Asian nations.
India may have to lower the import duty on pharmaceuticals for Peru in the discussions on the proposed free trade agreement (FTA) with the South American country.
The present Indian government has relaunched the talks with Israel. Israel wishes to conduct talks on regular basis to conclude the deal at the earliest. Indian patent system and pharmaceutical related issues have been the reasons why the deal couldn’t progress.
India’s position in the RCEP is the most protectionist among all the member nations. India has been resisting demands from Korea & Japan on intellectual property clauses, and other nations on opening up markets.
If the trade equation between India and Peru is in imbalance it would be causing more harm than benefit to India.
Negotiations are now nearing completion and there are increasing concerns among public health advocates, patient and consumer organisations, and other stakeholders, both in Europe and the Americas.
EU-MERCOSUR trade negotiations must not impose TRIPS Plus provisions on protection and enforcement of intellectual property rights.
The adoption of the measures proposed by the EU could put the sustainability of access to health policies in Brazil at risk, as they could sharply increase public expenditures on medicines.
The latest plan to get the controversial trade deal up and running involves freezing some of its controversial rules, including rules for biologic drugs, an expensive class of medicines often used to treat conditions such as cancer and rheumatoid arthritis.
As the TPP-11 meet to attempt to revive the TPP without the US, the research findings show how damaging the original medicine proposals would be.
India firm in opposing proposals that could hinder global access to affordable generic drugs
Healthcare watchers are calling on India to resist RCEP
Access to health products is non-negotiable; the Indian Government should reject the bullying tactics of the US based medical device industry.
RCEP negotiations should not restrict global access to affordable medicines and vaccines
The RCEP has hidden costs for people’s lives
RCEP will give multinational corporations unprecedented rights